Floatz logo

js111

Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Shanghai Junshi Bioscience Co., Ltd.Phase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations cohort.

Asset / SponsorPhaseRating
js212
Shanghai Junshi Bioscience Co., Ltd.
Phase 2CCC
js212 for
Shanghai Junshi Bioscience Co., Ltd.
Phase 2CCC

Same molecule, other indications

js111 is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
lung cancerDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →